Iovance ups full-year sales outlook to $410M–$420M on wider Amtagvi rollout
The US cell therapy company now expects 2026 sales well above its earlier $350M–$370M range, after about $122M in third-quarter revenue and growth in hospitals cleared to give Amtagvi.
Iovance Biotherapeutics now expects 2026 revenue of $410M to $420M, against its earlier forecast of $350M to $370M. The midpoint rises by about $55M, from $360M to $415M. The new range appears in a corporate presentation dated 5 November 2026.
The same document puts third-quarter revenue at roughly $122M. It also says more than 100 hospitals and clinics were cleared to administer Amtagvi (lifileucel) as of 5 November. The company ties the stronger outlook to the growth of that network. The material available to us does not break out sales by country, patient numbers or pricing.
On the balance sheet, Iovance reported about $382M in cash at 30 September 2026. The company says this funds operations well into 2029.
The presentation also looks ahead. It refers to Amtagvi approvals in several markets and a possible further approval in the first quarter of 2027, with submissions planned for 2027. It lists label-expansion trials in lung cancer, sarcoma and endometrial cancer. The summary we have does not say which countries or indications the 2027 approval and submissions cover.
Why it matters
- A guidance increase of about $55M at the midpoint, paired with a growing site network, indicates the commercial rollout is gathering pace.
- Context: cell therapies depend on specialised hospitals to deliver treatment, so the number of cleared sites is a practical gauge of patient access.
- Cash that the company says lasts into 2029 gives Iovance time to pursue its 2027 filings and expansion trials, but the markets and indications involved remain unspecified.
- Lung cancer, sarcoma and endometrial cancer trials mark where Iovance may seek to widen Amtagvi's use beyond its current approvals.
Company's press release (SEC filing): Iovance Biotherapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
